Compare DCTH & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCTH | ENTA |
|---|---|---|
| Founded | 1988 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.5M | 382.7M |
| IPO Year | 2015 | 2012 |
| Metric | DCTH | ENTA |
|---|---|---|
| Price | $12.59 | $14.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $22.00 | $20.40 |
| AVG Volume (30 Days) | ★ 579.8K | 230.3K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.53 | 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $102,814,000.00 |
| Revenue This Year | $24.54 | $7.76 |
| Revenue Next Year | $33.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $8.12 | $6.44 |
| 52 Week High | $13.44 | $17.15 |
| Indicator | DCTH | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 63.23 | 63.34 |
| Support Level | $10.26 | $13.19 |
| Resistance Level | N/A | $15.48 |
| Average True Range (ATR) | 0.57 | 0.77 |
| MACD | 0.12 | 0.33 |
| Stochastic Oscillator | 76.05 | 92.54 |
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.